Could SGLT2 inhibitors be the next 'game changer' in focal segmental glomerulosclerosis?

Affiliations

Editorial

Anthony T P Chan et al. Nephrol Dial Transplant. 2022.

. 2022 Aug 22;37(9):1593-1594.

doi: 10.1093/ndt/gfac139.

¹ Division of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

No abstract available

Keywords: SGLT2 inhibitor; focal segmental glomerulosclerosis; nondiabetic CKD; podocytopathy.

Comment on

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJV, Rossing P, Nowicki M, Wittmann I, Correa-Rotter R, Sjöström CD, Toto RD, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Nephrol Dial Transplant. 2022 Aug 22;37(9):1647-1656. doi: 10.1093/ndt/gfab335. Nephrol Dial Transplant. 2022. PMID: 34850160 Free PMC article. Clinical Trial.